The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2020 | MDS prognostic scores
Argiris Symeonidis, MD, PhD, University of Patras, Patras, Greece, discusses the prognostic scoring system and independent variables used to assess the severity of a patient’s myelodysplastic syndrome (MDS). He also highlights some of the specific comorbid conditions such as cardiovascular disease, which cause non-leukemic death. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
